Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Achillion partners with J&J to develop hepatitis C drugs

Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time.

Published
20 May 2015
From
Reuters
Gilead triple combination cures easy-to-treat hepatitis C patients in 6 weeks, but 4 weeks is not enough

A six-week regimen of sofosbuvir (Sovaldi) plus two experimental direct-acting antivirals being developed by Gilead Sciences cured more than 90% of previously untreated people with genotype 1 hepatitis

Published
15 May 2015
By
Liz Highleyman
Shortening hepatitis C treatment to 6 weeks effective but not perfect for easier-to-treat patients

Shortening hepatitis C treatment to 6 weeks for easier-to-treat patients without cirrhosis does not greatly reduce the efficacy of hepatitis C treatment for people with genotype 1

Published
15 May 2015
By
Keith Alcorn
Sofosbuvir-based therapy effective for hepatitis C patients with decompensated cirrhosis

Interferon-free regimens containing sofosbuvir (Sovaldi) plus simeprevir (Olysio) cured about three-quarters of people with genotype 1 chronic hepatitis C with advanced cirrhosis and MELD scores >10 in

Published
11 May 2015
By
Liz Highleyman
Gilead triple combination cures easy-to-treat hepatitis C patients in 6 weeks, but 4 weeks is not enough

A 6-week regimen of sofosbuvir (Sovaldi) plus two experimental direct-acting antivirals being developed by Gilead Sciences cured more than 90% of previously untreated people with genotype 1 hepatitis

Published
07 May 2015
By
Liz Highleyman
ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy

The Phase III programme will evaluate the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-,NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed. In the clinical trials, dolutegravir and rilpivirine will be provided as individual tablets; development of the single-tablet formulation will be concurrent with conduct of the trials.

Published
06 May 2015
From
Viiv Healthcare press release
When a short course of sofosbuvir/ledipasvir fails, some people can be cured of hepatitis C with a double treatment duration

More than 70% of people with chronic genotype 1 hepatitis C who did not achieve a sustained virological response when treated with sofosbuvir/ledipasvir (Harvoni) for 8 or 12

Published
01 May 2015
By
Liz Highleyman
Sofosbuvir plus pegylated interferon/ribavirin is highly effective for people with hard-to-treat genotype 3 hepatitis C

A throwback regimen of sofosbuvir (Sovaldi), ribavirin and pegylated interferon taken for 12 weeks cured 93% of people with hepatitis C virus (HCV) genotype 3 – substantially

Published
28 April 2015
By
Liz Highleyman
Sofosbuvir, daclatasvir and ribavirin cures hepatitis C for most people with advanced cirrhosis or liver transplants

An interferon-free regimen of sofosbuvir, daclatasvir and ribavirin for 12 weeks produced sustained response rates of 83% for people with hepatitis C virus (HCV) who had advanced

Published
28 April 2015
By
Liz Highleyman
Grazoprevir/elbasvir highly effective in treatment-experienced and HIV-coinfected hepatitis C patients

The combination of grazoprevir and elbasvir without ribavirin is highly effective in curing hepatitis C infection in 12 weeks in some groups of treatment-experienced patients and in

Published
25 April 2015
By
Keith Alcorn

Filter by country